RU2472509C2 - Способ лечения артрита - Google Patents

Способ лечения артрита Download PDF

Info

Publication number
RU2472509C2
RU2472509C2 RU2010123796/15A RU2010123796A RU2472509C2 RU 2472509 C2 RU2472509 C2 RU 2472509C2 RU 2010123796/15 A RU2010123796/15 A RU 2010123796/15A RU 2010123796 A RU2010123796 A RU 2010123796A RU 2472509 C2 RU2472509 C2 RU 2472509C2
Authority
RU
Russia
Prior art keywords
methyl
amino
benzoyl
piperazin
phenylsulfanyl
Prior art date
Application number
RU2010123796/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2010123796A (ru
Inventor
Филип БАРДУЭЛЛ
Тарик ГХАЮР
Original Assignee
Эбботт Лэборетриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Лэборетриз filed Critical Эбботт Лэборетриз
Publication of RU2010123796A publication Critical patent/RU2010123796A/ru
Application granted granted Critical
Publication of RU2472509C2 publication Critical patent/RU2472509C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2010123796/15A 2007-11-16 2008-11-14 Способ лечения артрита RU2472509C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98847907P 2007-11-16 2007-11-16
US60/988,479 2007-11-16
PCT/US2008/083478 WO2009064938A1 (en) 2007-11-16 2008-11-14 Method of treating arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2012143212/15A Division RU2526201C2 (ru) 2007-11-16 2008-11-14 Способ лечения артрита

Publications (2)

Publication Number Publication Date
RU2010123796A RU2010123796A (ru) 2011-12-27
RU2472509C2 true RU2472509C2 (ru) 2013-01-20

Family

ID=40291332

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2012143212/15A RU2526201C2 (ru) 2007-11-16 2008-11-14 Способ лечения артрита
RU2010123796/15A RU2472509C2 (ru) 2007-11-16 2008-11-14 Способ лечения артрита

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2012143212/15A RU2526201C2 (ru) 2007-11-16 2008-11-14 Способ лечения артрита

Country Status (14)

Country Link
US (2) US20090176785A1 (OSRAM)
EP (1) EP2231159A1 (OSRAM)
JP (2) JP5450434B2 (OSRAM)
KR (1) KR101585848B1 (OSRAM)
CN (1) CN101969951B (OSRAM)
AU (1) AU2008322595B2 (OSRAM)
CA (1) CA2705294C (OSRAM)
DO (1) DOP2013000169A (OSRAM)
IL (2) IL205501A (OSRAM)
MX (1) MX2010005395A (OSRAM)
NZ (2) NZ601350A (OSRAM)
RU (2) RU2526201C2 (OSRAM)
WO (1) WO2009064938A1 (OSRAM)
ZA (1) ZA201003434B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2957558A3 (en) 2010-03-25 2016-03-02 AbbVie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
NZ608274A (en) 2010-10-29 2015-05-29 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
SG190361A1 (en) 2010-11-23 2013-06-28 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
MY165884A (en) 2010-11-23 2018-05-18 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN111511748B (zh) 2017-08-23 2023-05-02 广州麓鹏制药有限公司 Bcl-2抑制剂
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
US20220372042A1 (en) 2019-10-03 2022-11-24 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
CA3160091A1 (en) 2019-11-05 2021-05-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
CA3173041A1 (en) 2020-02-24 2021-09-02 Guangzhou Lupeng Pharmaceutical Company Ltd. Hot melt extruded solid dispersions containing a bcl2 inhibitor
WO2022140224A1 (en) 2020-12-22 2022-06-30 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965745A (en) * 1995-10-10 1999-10-12 Pfizer Inc Indole carbamates as leukotriene antagonists
WO2005049594A1 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20070027135A1 (en) * 2005-05-12 2007-02-01 Milan Bruncko Apoptosis promoters

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
HUP0300235A2 (hu) * 2000-03-21 2003-08-28 The Procter & Gamble Co. Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MX242553B (es) * 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
CN100591679C (zh) * 2003-07-28 2010-02-24 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并唑衍生物及其作为lta4h调节剂的应用
ES2441206T3 (es) * 2003-09-03 2014-02-03 Raqualia Pharma Inc. Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
US20080182845A1 (en) * 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965745A (en) * 1995-10-10 1999-10-12 Pfizer Inc Indole carbamates as leukotriene antagonists
WO2005049594A1 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20070027135A1 (en) * 2005-05-12 2007-02-01 Milan Bruncko Apoptosis promoters

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
НАСОНОВА В.А. и др. Клиническая ревматология. - М.: Медицина, 1989, с.16-23. *

Also Published As

Publication number Publication date
AU2008322595B2 (en) 2014-01-30
JP2014065716A (ja) 2014-04-17
JP2011503199A (ja) 2011-01-27
RU2010123796A (ru) 2011-12-27
KR101585848B1 (ko) 2016-01-15
CN101969951B (zh) 2012-10-31
IL205501A (en) 2013-08-29
CA2705294C (en) 2016-05-17
CA2705294A1 (en) 2009-05-22
WO2009064938A1 (en) 2009-05-22
WO2009064938A9 (en) 2009-08-06
RU2012143212A (ru) 2014-04-20
US20160101109A1 (en) 2016-04-14
RU2526201C2 (ru) 2014-08-20
NZ601350A (en) 2013-08-30
AU2008322595A1 (en) 2009-05-22
US20090176785A1 (en) 2009-07-09
DOP2013000169A (es) 2013-12-15
JP5667684B2 (ja) 2015-02-12
IL227641A0 (en) 2013-09-30
ZA201003434B (en) 2011-10-26
EP2231159A1 (en) 2010-09-29
MX2010005395A (es) 2010-06-02
JP5450434B2 (ja) 2014-03-26
CN101969951A (zh) 2011-02-09
NZ585085A (en) 2012-08-31
KR20100099172A (ko) 2010-09-10
IL205501A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
RU2472509C2 (ru) Способ лечения артрита
US20080182845A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US20160175316A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
EP2101759B1 (en) Methods of using mek inhibitors
JP2005538099A5 (OSRAM)
JP2016539927A (ja) Ｊａｋ１選択的阻害剤とその使用
RU2012127306A (ru) Новые трициклические соединения
JP2012517446A (ja) Ｓ１ｐ５受容体の作動薬および拮抗薬ならびにそれらの使用方法
RU2010153582A (ru) Новые трициклические соединения
FI3856341T3 (fi) (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä
US20110184025A1 (en) Methods and Compositions Using Immunomodulatory Compounds for the Treatment and Management of Spirochete and Other Obligate Intracellular Bacterial Diseases
US20230405015A1 (en) Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
RU2011111117A (ru) Лечение аутоиммунных заболеваний
JP2019533639A5 (OSRAM)
RU2001121989A (ru) Производные (1-фенацил-3-фенил-3-пиперидилэтил)пиперидина, способы их получения и содержащие их фармацевтические композиции
TW202327611A (zh) 使用ｂｔｋ抑制劑和ｐ１３激酶抑制劑的組合治療癌症之方法
JP4598674B2 (ja) 統合失調症治療剤
RU2786570C2 (ru) Комбинированная терапия тетрациклическими аналогами хинолона для лечения рака
RU2021138469A (ru) ИНГИБИТОРЫ ДОФАМИН-β-ГИДРОКСИЛАЗЫ
HK1169037B (en) Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20161115